Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Next-Generation Antibody Players

This article was originally published in Start Up

Executive Summary

A host of companies are vying to develop new and improved antibodies. Technologies span the gamut from improving ADCC effector function to stripping away components of traditional antibodies to create leaner molecules that may be cheaper to manufacture and eaiser to deliver orally. These start-ups remain product focused, eschewing the platform technology model. Pharmaceutical and established biotechnology companies are eager to get their hands on the technologies, causing a flurry of deal-making in the last year.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts